Podcasts about Genomics

The current Ebola outbreak in the Democratic Republic of the Congo and neighboring Uganda is caused by the Bundibugyo virus. There's no specific treatment or vaccine for this strain, unlike the more common Zaire strain that caused the 2014 outbreak.  Molecular biologist Christian Happi has dedicated his career to improving genomic sequencing capabilities and virus monitoring across the continent of Africa. He joins Flora to discuss the challenges of the current outbreak and his vision for better disease surveillance.  Guest: Dr. Christian Happi is a distinguished professor at Redeemer's University and runs the Institute of Genomics and Global Health in Nigeria. Other episodes you may enjoy: Inside the Nebraska quarantine facility responding to hantavirus Can ‘Suggestion-Box Science' Make Public Health More Useful? Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In the late 1980s, a child exposed to fallout from the Chernobyl disaster lay in a hospital bed while doctors told his family there were no clear answers and no reliable path forward. Decades later, that same child, Yan Leyfman, walks into exam rooms as a hematology oncology fellow, expected to deliver clarity inside a system that still runs on delay, uncertainty, and institutional self preservation.This episode traces the throughline from early life shaped by radiation exposure and hospice level uncertainty to a career inside academic medicine, translational research, and oncology media. Yan built his identity around survival and usefulness, moving from patient to physician while carrying the memory of what it feels like to sit on the other side of the table. He helped launch MedNews Week during the COVID crisis to push back on misinformation and expand access to medical knowledge, stepping into a public role while still in training.The conversation stays grounded in the friction between personal narrative and system reality. Clinical training demands efficiency, hierarchy, and emotional distance. Cancer care demands time, clarity, and human connection. Those forces collide in real patient encounters where prior authorization delays, insurance barriers, and fragmented care pathways shape outcomes as much as any treatment protocol.Yan speaks openly about mentorship, belonging, and the drive to make meaning out of survival. The discussion pushes further into what the healthcare system actually rewards, what it quietly strips away, and how quickly empathy can erode under institutional pressure. The episode also examines the role of medical media, where education, industry influence, and narrative control often blur together.This is a conversation about identity under construction, about what happens when someone who remembers powerlessness steps into a role that carries authority, and about whether that memory can survive long enough to change anything.RELATED LINKSYan Leyfman on LinkedInYan Leyfman on InstagramSurviving ChernobylFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Howie is joined by guest host Megan Ranney, dean of the the Yale School of Public Health, for a live episode recorded at the Yale Innovation Summit, featuring conversations with five innovators at the intersection of healthcare, public health, and entrepreneurship. Jaya Dadwal, a recent graduate of the School of Public Health and founder of forEVA Health, focused on raising healthcare standards for the female body Monique Rainford, a Yale School of Medicine ob-gyn and founder of Enrich Health, focused on addressing disparities in maternal health Kimberley Steele, a bariatric surgeon and program director at the federal Advanced Research Projects Agency for Health (ARPA-H) Yusuf Ransome, a faculty member at the School of Public Health and founder of Soul Health, a faith tech solution focused on addressing the mental wellbeing of the "missing middle" Janani Ramaswamy, head of IP and licensing services at Yale Ventures Show notes: The Yale Innovation Summit Yale Innovation Summit 2026 Yale Ventures Jaya Dadwal forEVA  FDA: Essure Permanent Birth Control "Problems Reported with Essure" Jennifer McFadden "Women's Health Strategy for England" A UK government report including the finding that 84% of women report that their voices have not been listened to in the healthcare system. Polyendocrine metabolic ovarian syndrome (PMOS) Monique Rainford Megan Ranney and Monique Rainford: "Opinion: Over-the-counter birth control pill could make a huge difference" Enrich Health Monique Rainford: Pregnant While Black: Advancing Justice for Maternal Health in America Sejal Hathi: "Nine Months of Medical Attention. Then Almost Nothing" Kimberley Steele Advanced Research Projects Agency for Health (ARPA-H) Lymphatic System: Function, Conditions & Disorders ARPA-H: Lymphatic Imaging, Genomics, and Phenotyping Technologies (LIGHT) ARPA-H: Groundbreaking Lymphatic Interventions and Drug Explorations (GLIDE) "GLIDE set to prevent and cure human disease by targeting the lymphatic system" Yusuf Ransome Yusuf Ransome  on LinkedIn: "The hardest part of building a solution is when your own family depends on it" SOCAH Lab Pew Research: "Spirituality Among Americans" Janani Ramaswamy "Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer" Arvinas Yale Ventures: Accelerators, Programs, and Innovation Centers HealthTech Works In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.

Matthew Zachary is a brain cancer survivor, healthcare advocate, founder of Stupid Cancer and We the Patients, and host of Out of Patients. In April 2026, he returned to the stage at Merkin Hall near Lincoln Center for his first solo public piano concert in almost 22 years while launching his debut book, We the Patients: Understanding, Navigating, and Surviving America's Healthcare Nightmare.What unfolded became far larger than a concert.Over 2 hours, survivors, clinicians, advocates, nonprofit founders, journalists, pharmaceutical sponsors, and healthcare insiders gathered in one room to reflect on 30 years of survivorship, institutional failure, accidental advocacy, and the emotional afterlife of cancer. The evening moved through original piano performances, live chapter readings, and deeply personal conversations about infertility, disability, financial toxicity, insurance denials, grief, burnout, and what happens when patients spend decades navigating systems designed around transactions instead of continuity.Guests including Wendell Potter, Maimah Karmo, Craig Lustig, Shelly Fuld Nasso, Tamika Felder, and others reflected on how the modern cancer advocacy movement emerged largely because patients built parallel systems where healthcare infrastructure failed to meet human needs. The conversation explored how prior authorization, reimbursement incentives, administrative fragmentation, and institutional distrust continue shaping the patient experience across oncology and survivorship.The performance also marked a deeply personal milestone. After brain cancer compromised his left hand at age 21, Zachary spent 6 months rehabilitating both hands to return to public performance for the first time in over 2 decades. The result became part concert, part civic gathering, and part historical record of a generation of survivors who refused to disappear quietly.RELATED LINKSMZLIVE Official WebsiteMZLIVE YouTube VideoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In December 1996, a 37 year old pharmaceutical executive sat in a Borders bookstore reading medical textbooks on the floor, trying to understand a disease she had never heard of. Multiple myeloma carried a three year prognosis. Her daughter was 18 months old. Her father had just died of cancer. Within weeks, she pushed her doctors to say the quiet part clearly. This would likely end her life before her child entered kindergarten.Kathy Giusti refused to accept passive survival. She built a plan while the system offered fragments. She interviewed oncologists and fertility specialists at the same time. She pursued IVF to have a second child while preparing for treatment. She stayed employed to keep insurance coverage. Every decision carried financial, medical, and emotional risk.That same urgency exposed a deeper failure. Cancer research moved slowly. Academic centers guarded data. Clinical trials lacked coordination. Patients entered a system that demanded compliance without providing clarity. Giusti responded by building the Multiple Myeloma Research Foundation, not as a support group, but as an operating engine to accelerate drug development, fund research, and force collaboration across institutions.This episode tracks the tension between individual agency and systemic failure. Giusti describes how patients navigate diagnosis, insurance barriers, and fragmented care in real time. She explains how data, genomics, and clinical trials reshape cancer treatment while still leaving patients responsible for decisions they are not trained to make. She addresses disparities in access, the limits of early detection, and the reality that progress in oncology often depends on speed, funding, and alignment of incentives.The conversation moves between lived experience and structural critique. It names the cost of delay, the burden placed on patients to act as their own advocate, and the tradeoffs required to push a system forward that still protects itself first.⸻RELATED LINKSKathy GiustiMultiple Myeloma Research FoundationFatal to FearlessAmerican Society of Hematology⸻FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Dr. Paloma Giangrande, Editor-in-Chief of Molecular Therapy Nucleic Acids, speaks with Normand Allaire, Head of Genomics at the Cystic Fibrosis Foundation Therapeutics Lab. They discuss the article, Upregulation of a CFTR mRNA isoform has therapeutic potential for the treatment of 3’ CFTR PTC variants, which introduces an ASO-based therapeutic approach to cystic fibrosis for the 10% of patients who lack an approved treatment. Music: 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

In today's episode, we welcomed Pedram Razavi, MD, PhD, and Dara S. Ross, MD. Dr Razavi is a breast medical oncologist and director of Liquid Biopsy & Genomics at Memorial Sloan Kettering Cancer Center in New York, New York. Dr Ross is an associate attending pathologist at Memorial Sloan Kettering Cancer Center.In our exclusive interview, Drs Razavi and Ross discussed the evolution of ESR1 mutation–directed breast cancer management, emphasizing the role of comprehensive genomic testing at metastatic recurrence, including liquid biopsy and tissue sequencing. They highlighted that ESR1 mutations can develop in patients receiving aromatase inhibitors and that the detection of these mutations is crucial for treatment decisions. They also highlighted findings from the phase 3 SERENA-6 trial (NCT04964934), which tested switching to camizestrant upon the emergence of an ESR1 mutation during treatment with an aromatase inhibitor and a CDK4/6 inhibitor ahead of radiographic disease progression in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Despite concerns from the FDA's Oncologic Drugs Advisory Committee (ODAC) about SERENA-6's design and overall survival outcomes, the experts praised the trial's innovative approach to personalizing breast cancer management based on biomarkers and noted ways that the ODAC decision may affect future clinical research in this field.

At 19, Shlomit woke up unable to speak. The right side of her body went numb. An emergency room sent her home and called it stress. That moment did not end in a diagnosis that changed policy or triggered reform. It sent her into a decade long pursuit of understanding how the brain fails language and how the healthcare system fails patients who cannot advocate for themselves.Shlomit trained as a speech language pathologist and spent years inside acute care hospitals and ICUs, performing endoscopies and treating patients with brain injury, stroke, and dysphagia. She watched medical teams rotate in and out, deliver dense updates, and leave families nodding without comprehension. She stayed behind and translated. Every day, patients told her she was the only one who explained what was happening. That gap is not an accident. Hospital systems optimize for throughput, not understanding. Patients move through beds based on cost, not readiness. Discharge planning becomes a financial decision wrapped in clinical language. A stay under 48 hours can shift the insurance burden dramatically, leaving patients exposed to higher out of pocket costs. Shlomit left the system and built Patient Path NYC, a private patient advocacy service. She now spends 15 to 20 hours a week per client reading charts, coordinating care teams, and translating medical decisions into plain language. Her work sits in the uncomfortable space between healthcare policy and lived experience. Families pay out of pocket to understand their own care. Hospitals benefit from the clarity she provides while maintaining the same structural incentives that created the confusion.This conversation tracks the human cost of fragmented care, the economics behind discharge decisions, and the quiet reality that patients who cannot communicate clearly often lose control of their own outcomes.RELATED LINKSShlomit LibertyShlomit Liberty on LinkedInPatient Path NYCBoard Certified Patient AdvocateFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Precision medicine is changing the future of women's health by helping clinicians move beyond labels and uncover the true root causes driving symptoms. In this episode, Dr. Jen sits down with Dr. Sharon Hausman-Cohen, co-founder of IntellxxDNA, to explore how actionable genomics can personalize care for fertility, menopause, ADHD, autism, cognitive health, and chronic illness. They discuss how genetics influence oxidative stress, inflammation, estrogen metabolism, sleep, neurotransmitters, and nutrient pathways, and why understanding someone's unique biology allows for more targeted interventions instead of endless trial and error. This conversation offers a fascinating look at how genomics and epigenetics can help women optimize health at every stage of life. Dr. Sharon Hausman-Cohen is a Harvard-trained physician and the co-founder of IntellxxDNA, a precision medicine genomics platform designed to help clinicians uncover root causes behind complex health conditions. With a background in research and clinical medicine, she specializes in actionable genomics related to cognitive health, women's health, fertility, pediatrics, and chronic illness. Through IntellxxDNA, Dr. Hausman-Cohen helps practitioners use genetic insights to create highly personalized “N of 1” treatment plans focused on prevention, resilience, and long-term wellness. Website: https://intellxxdna.comInstagram: https://www.instagram.com/intellxxdnaLinkedIn: https://www.linkedin.com/company/intellxxdnaYouTube: https://www.youtube.com/@intellxxdnaFacebook: https://www.facebook.com/intellxxdnaPODCAST: Thank you for listening please subscribe and share! Shop supplements: https://healthybydrjen.shop/CHECK OUT a list of my Favorite products here: https://www.healthybydrjen.com/drjenfavoritesFOLLOW ME:Instagram: https://www.instagram.com/integrativedrmom/Facebook:  https://www.facebook.com/integrativedrmomYouTube: https://www.youtube.com/@integrativedrmomFTC: Some links included in this description might be affiliate links. If you purchase a product through one of them, I will receive a commission (at no additional cost to you).  I truly appreciate your support of my channel. Thank you for watching! Video is not sponsored.DISCLAIMER: This podcast does not contain any medical or health related diagnosis or treatment advice. Content provided on this podcast is for informational purposes only.  For any medical or health related advice, please consult with a physician or other healthcare professionals. Further, information about specific products or treatments within this podcast are not to diagnose, treat, cure or prevent disease.

What does it take to build the data systems that sit behind your genetic evaluations?This week on the podcast, Ferg catches up with Dan Garrick from Helical. Dan grew up on a sheep, beef and venison farm in the Manawatu before moving to the US at 13, where he went on to complete a PhD in aerospace engineering at Iowa State University. He's the son of Professor Dorian Garrick, one of New Zealand's most respected animal breeding geneticists, and his grandfather was one of the world's leading experts on sharks, making Dan a third-generation PhD.Dan explains how the same maths used to model fluid dynamics around rockets is used to generate breeding values, and how he ended up joining the family business in 2017 to help roll out some of the first production single step evaluations in the US for American Hereford and IGS. That work quickly revealed a major bottleneck in managing the genomic data flowing in from DNA testing labs. That's where Helical was born.Ferg and Dan talk through how Helical now serves breed societies, genetics companies, universities and labs across beef, dairy, sheep, horses, dogs, aquaculture and forestry. They also look ahead at where things are going. From decision support tools and AI in commercial herds, to the potential for wearable devices like virtual fencing collars to generate entirely new breeding values nobody has thought of yet - both Dan and Ferg agree the future is bright for Agriculture. Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, Heiniger Australia and New Zealand, and ProWay Livestock Equipment. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out the MSD range HERECheck out Allflex products HERECheck out Heiniger's product range HERECheck out ProWay's product range HERE

The following article of the Tech industry is: “Ethical Genomics: The Key to Sustainable Innovation” by Jorge Melendez Zajgla, General Director, Instituto Nacional de Medicina Genomica.

In 2020, developmental biologist Dr. Crystal Rogers drove the country roads outside Davis, California crying between grant rejections, wondering whether she was about to lose her lab, her career, and the scientific future she had spent years building. She had already done what academia tells young scientists to do. She earned the credentials. She landed a faculty position at UC Davis. She built a lab. Then the real test began.On this episode of Standard Deviation, Dr. Oliver Bogler examines the unspoken rules that determine which scientists survive academic research and which quietly disappear from it. The conversation follows Crystal Rogers and cancer biologist Dr. Michelle Mendoza as they collide with the “Hidden Curriculum” of biomedical science: the unwritten rhetoric, institutional signaling, and grant writing strategies that often decide who receives funding, tenure, and long term stability.Michelle Mendoza entered a tenure track position at the Huntsman Cancer Institute while raising 3 children, navigating a divorce, and trying to secure major NIH funding during COVID. What looked like objective scientific review turned out to depend heavily on persuasion, presentation, and insider fluency. Established researchers could promise massive research agendas based on reputation alone. Junior investigators faced a completely different standard.Oliver traces how the Life Science Editors Foundation and its JEDI program intervened by pairing scientists with former editors from journals including Cell and Nature. The work had little to do with commas or grammar. Editors challenged logic, structure, and scientific framing before grant reviewers could destroy an application in public.Both researchers eventually secured career defining grants. One realized she would keep her job and not have to move her family. The other celebrated by ordering a personalized “DEV BIO” license plate and driving through Davis blasting nineties hip hop and Beyoncé.The episode exposes how biomedical research funding rewards institutional fluency as much as scientific talent, and how hidden systems inside academic medicine continue shaping who gets to stay in science long enough to make discoveries.RELATED LINKSDr. Crystal Rogers LinkedInDr. Crystal Rogers Faculty PageDr. Crystal Rogers LabDr. Michelle Mendoza LinkedInDr. Michelle Mendoza Faculty PageHuntsman Cancer Institute Mendoza LabLife Science Editors FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this explainer episode, we've asked Kate Stanbury, research midwife on the Generation Study, to tell us more about the vital role that midwives play. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: What does a midwife do? My name is Florence Cornish, and today I'm joined by Kate Stanbury, who is a research midwife working on the Generation Study, and she is going to be explaining the vital role that midwives play. So, to start off with Kate, I'm sure that most of our listeners will have heard of midwives before or maybe even like come across them in healthcare settings, but it would be good to hear from you more about what a midwife actually does. Kate: Yeah, absolutely. So, a midwife is someone who provides care and support to birthing people and their families during pregnancy, labour, and after birth as well. A lot of people just think of midwives as delivering babies, but we do a lot of other stuff around that as well. There are lots of different types of midwives as well, so we've got community midwives that might come out to your home and see you and your baby. We've got specialist midwives who might have a certain medical condition that they're experts in. And then we also have people like myself who are research midwives as well. Florence: So, you talked about a couple of different types of midwives there. Could you tell me more about the specific type of midwife that you are? Kate: Yeah, so a research midwife, as the name suggests, does research, so I also look after women during their pregnancy as well. A lot of the research that we do relates to sort of high-risk pregnancies, and so we approach women for specific research studies that might have a particular characteristic that we are investigating. We also recruit patients to these studies. We look after them during their pregnancies when they're taking part in the studies, and then we follow them up after their birth as well to collect data and see if what we've done as part of the research has had an impact. Florence: And so you are working on the Generation Study, and if any listeners want to learn more about that, then they can check out our previous Genomics 101 episode, What is the Generation Study? Kate, could you tell me a little bit more about what led you to become a midwife? Like what was the journey that you took to get to this point? Kate: Yeah, so I started my degree in midwifery straight out of college. So, I was quite young at the time, I was 18. I went to university, did a three-year degree to get a bachelor's of midwifery. That is probably the most common route that people go through in terms of to become a midwife, but some people choose to do adult nursing first, and then they can do a conversion course into midwifery, which is about 18 months long as well. So that's usually the most common route. I was sort of drawn to the occupation because one of my close friends, her mum was a midwife, so I used to see her in their lounge. They used to have lots of cards and things that she would display from patients that she'd looked after, which was really nice. Florence: And so what makes you passionate about working in the Generation Study and what motivates you in your role? Kate: I think being able to have an impact on how we can improve care, I think that's really important. Obviously everything that we do is evidence-based, so that's what really drew me to become a research midwife and being able to take part in research studies that we can look back on in the future and say, “oh, I was part of that, and because of that we've been able to improve the lives of families and babies going forward.” That's really important to me. Florence: Yeah. And, and just building off of that, have there been any specific moments that have like stood out to you during your time working on the study? Kate: Yeah, I think being able to see it from its starting point, so as a research midwife as well as working on the Generation Study. I sort of see people in clinics, I tell them about the study and then they might sign up to it.  But then the other half of my role is a re regional results coordinator for the Generation Study. So I might then see that patient come through to me with a condition suspected result, and being able to follow that family through their sort of patient journey, from consent taking part in the study to getting their baby into NHS care, that potentially we might be able to give treatments really quickly for a baby that might have a really rare genetic problem. And being able to see that that process works really well and improves those outcomes for that baby and that family. That's really, really something that's amazing to see and what I'm really looking forward to in the future as well. Florence: Yeah, I can imagine that like getting to experience the kind of like end to end, like see it. Kate: Yeah, absolutely. Yeah. Florence: Super cool. Kate: We don't often get to follow the babies up in my line of work, so it's really nice. Florence: Yeah. Yeah. I'd also be curious to know has being involved in the Generation Study changed how you think about the space? So whether that's genomics or research or even your role as a midwife, do you see any of those things differently now? Kate: Yeah, absolutely. I think before I started this role with the Generation Study, genomics was sort of there, but I didn't really know the full details and like much in depth knowledge about genomics and how that could impact on people's health and their pregnancies and their health going forward into the future. But since doing this job, I think it's really opened my eyes to how much of an impact it can have and how much I think it could potentially improve the lives of generations to come. Florence: Well, thank you so much, Kate. I think we'll finish there, but I really appreciate you taking the time to come on our podcast. Kate: Thank you. Thanks for having me. Florence: If you want to hear more explainer episodes like this, you can find them on our website at www.genomicsengland.co.uk or wherever you get your podcasts. Thank you for listening.

In 2008, Katy Talento walked away from Capitol Hill and into a Catholic convent. Within a year, she walked out. Within another decade, she sat inside the White House shaping health policy. Somewhere in between, she got labeled “infertile” after a single cycle of testing and spent years believing it.That label stuck. The pain that came before it never got investigated. Doctors offered birth control and moved on. No one asked why her body was struggling. No one followed the thread.Talento built her career inside the very systems she now critiques. She worked on federal health policy, global disease programs, and later advised the Trump administration on healthcare reform. She helped advance price transparency rules in a system where hospitals can still list 457 different prices for the same service.Then she left.Now she builds employer health plans that bypass insurers, PBMs, and traditional networks. Her approach replaces insurance contracts with direct payment, nurse navigators, and cost sharing models that promise simplicity but raise hard questions about risk and protection.This conversation sits in that tension.Talento describes a healthcare system shaped by layered incentives, where insurers, hospitals, and intermediaries profit from complexity. She argues that employers hold the leverage to disrupt it. The host pushes on what happens when patients fall outside those structures, when contracts disappear, and when community based models fail.The episode moves through infertility, misdiagnosis, insurance design, and the mechanics of employer sponsored care. It tracks how policy decisions made in Washington ripple into exam rooms, billing departments, and family lives.It also confronts a harder truth.Even insiders who understand the system can still get caught in it.RELATED LINKSAllBetter HealthKaty TalentoThem Before UsAn Arm and a LegRelentless Health ValueFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of The Crop Science Podcast Show, Dr. Bob Stupar from the University of Minnesota explores soybean genomics, gene editing, and genomic selection in modern breeding. He explains how markers improve selection efficiency, why SCN resistance requires a multi-gene approach, and what the five-year strategic plan means for the soybean genomics community. Listen now on all major platforms!"The ability to use genomic information to predict and improve selection across entire breeding populations is growing, and even minor-effect genomic regions are becoming targets for practical breeding."Meet the guest: Dr. Bob Stupar is a Professor in the Department of Agronomy and Plant Genetics at the University of Minnesota. His research focuses on molecular genetics and genomics of legume crop species, including soybean and pea, with primary interests in the genetic basis of natural and induced phenotypic variation, developing novel genetic resources, and using genomic strategies for trait improvement.Liked this one? Don't stop now — Here's what we think you'll love!What you will learn:(00:00) Highlight(00:34) Introduction(04:20) Background(05:54) Genetics vs. genomics(10:11) Genomics in breeding(16:58) Biotechnology and GMOs(22:01) Strategic planning(27:39) Future of genomics(29:53) Final questionsThe Crop Science Podcast Show is trusted and supported by innovative companies like:- Loam Bio

European markets were weighed down by declines in the luxury sector yesterday, as concerns over weakening global demand dampened sentiment. In contrast, major US indices reached fresh record highs, led by strong gains in the technology sector. Meanwhile, oil prices are climbing again this morning amid signs that the Middle East ceasefire may be unravelling. Today, we are joined by Dr. Damien Ng from Next Generation Research, who will share his insights on the hantavirus outbreak and the role genomics and digital health tools are playing.(00:00) - Introduction: Bernadette Anderko, Product & Investment Content (00:34) - Markets wrap-up: Roman Canziani, Head of Product & Investment Content (06:21) - Genomics & digital health tools tackling the Hantavirus: Damien Ng, Next Generation Research (10:41) - Closing remarks: Bernadette Anderko, Product & Investment Content Would you like to support this show? Please leave us a review and star rating on Apple Podcasts, Spotify or wherever you get your podcasts.

It's no secret that students' interest in STEM keeps growing. With an overwhelming number of different fields to pursue and growing opportunities for high schoolers, where do they start? Summer Science Program International (SSPI) helps students develop a deeper love for STEM and research through SSPI's immersive, rigorous, and collaborative summer program. SSP is a highly competitive (10,000 applicants for about 700 spots this year) 60-year old STEM program (Summer Science Program) that empowers students to follow their passions and more importantly gives them the opportunity to participate in rote experiments and gain hands-on experience, vs. being taught about STEM.  Key program study topics include astrophysics, bacterial genomics, biochemistry and cell biology.These flagship summer programs are a rigorous five-week residential summer research experience designed for highly motivated high school juniors. Participants engage in advanced research in astrophysics, biochemistry, bacterial genomics, and synthetic chemistry while living on a college campus. Summer Science Program has offered participants “the educational experience of a lifetime” for over 66 years, and program alumni have gone on to leading positions in industry, business, innovation, and more.Amy Hee Kim joined SSP International in 2025 as the Chief Program Officer, bringing 15 years in STEM fields as well as her background as a physical chemist (PhD from University of Chicago). Before joining SSPI, Amy served as the Executive Director of EnCorps helping STEM professionals become teachers in under-resourced community schools.Connect with Amy & SSP International:Website: ssp.orgYouTube: @sspinternational Instagram: @summerscienceFacebook: @SummerScienceProgramAmy's email: amy.kim@ssp.org Amy's LinkedIn: linkedin.com/in/amy-hee-kim-b6507b7/Chris Woods is the host of the STEM Everyday Podcast... Connect with him:Website: dailystem.comTwitter/X: @dailystemInstagram: @dailystemYouTube: @dailystemGet Chris's book Daily STEM on AmazonSupport the show

Send us Fan Mail Genomic Data Scientist Career Guide: Salary, Scope & Skills in India and Abroad What if you could use DNA data, Artificial Intelligence, and coding to help predict diseases, improve treatments, and shape the future of medicine?Welcome to another future-ready episode of The Kapeel Gupta Career PodShow, where we decode powerful and emerging careers for students and professionals.In this episode, we explore one of the most exciting interdisciplinary careers of the future — Genomic Data Scientist. This is a career at the intersection of: 

Dr. Alex Young, a statistical geneticist and assistant professor in the Human Genetics department at UCLA, joins Steve Hsu to discuss the cutting edge of genomic prediction. They cover his research on polygenic embryo screening in IVF (including the ImputePGTA method), family-based DNA analysis, missing heritability, and the implications of polygenic scores for traits like education and disease. Alex also discusses his recent battles with cancer.https://x.com/AlexTISYoungChapter Markers:(00:00) - Alex Young Bio (06:36) - Biobank Era Genetics (10:49) - Missing Heritability Debate (27:18) - Embryo Selection Controversy (50:32) - Embryo Selection Backlash (53:42) - Mexico City Admixture Study (01:00:13) - Censorship Via Data Access Control (01:05:02) - Battle With Cancer and Circulating Tumor DNA (ctDNA) –Steve Hsu is Professor of Theoretical Physics and of Computational Mathematics, Science, and Engineering at Michigan State University. Previously, he was Senior Vice President for Research and Innovation at MSU and Director of the Institute of Theoretical Science at the University of Oregon. Hsu is a startup founder (SuperFocus.ai, SafeWeb, Genomic Prediction, Othram) and advisor to venture capital and other investment firms. He was educated at Caltech and Berkeley, was a Harvard Junior Fellow, and has held faculty positions at Yale, the University of Oregon, and MSU. Please send any questions or suggestions to manifold1podcast@gmail.com or Steve on X @hsu_steve.

In a wooded campground cabin in the early 2000s, 19 year old Ben Unger stood in the doorway and watched 20 naked men form a circle around a crying teenager. A counselor held up two tangerines and shouted, “These are your balls.” The exercise claimed to cure same sex attraction by forcing young men to “reclaim” their masculinity from overbearing mothers. Phones had been confiscated. Parents had paid thousands of dollars. Religion supplied the script. Pseudoscience supplied the props.Ben had grown up in an Orthodox Jewish community in Brooklyn and later studied in Israel to become a rabbi. When he admitted he felt attracted to men, rabbis told him to eat 7 figs a day, immerse in a ritual bath 5 times daily, or marry a woman and trust that “if there's friction, it works.” At 19, he entered conversion therapy through an organization called Jews Offering New Alternatives to Homosexuality, known as JONAH. He left with depression, religious trauma, and 6 months of silence toward the mother he had been taught to blame.Years later, represented by the Southern Poverty Law Center, Ben helped sue JONAH for consumer fraud in a landmark New Jersey case. The argument centered on evidence, not theology. Sexual orientation cannot be changed. The jury deliberated for 3 hours and ruled against the organization. The verdict helped reshape how states regulate conversion therapy and protect minors from psychological harm disguised as treatment.Today, Ben runs Buff Personal Training in New York City, a gym built on autonomy, mental health, and self respect. His story traces the arc from institutional control to self authorship. The conversation examines religion, LGBTQ rights, conversion therapy, consumer protection law, and the lasting cost of being told your identity is a disorder.RELATED LINKSBen Unger on LinkedInBen Unger on InstagramBUF Personal TrainingSouthern Poverty Law CenterJONAHFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, we celebrate 10 years of the Participant Panel and explore how genomic research is being guided by patient and participant voices.  Made up of people who have consented for their genome, or the genome of their loved one, to be included in the National Genomics Research Library, the Panel plays a vital role in shaping how research is designed, how data is used, and how genomics is communicated. From influencing policy discussions to to advising the Genomics England board, their work helps ensure lived experience is embedded from the very beginning.  Over the past decade, the Panel has driven meaningful change. From advocating for greater transparency and accessibility, to challenging how the genomics community talks about genetic conditions. But beyond the impact, this episode focuses on the people behind the work: their motivations, experiences, and the realities of representing a wider community.  Our host, Sharon Jones is joined by:  Kirsty Irvine – Chair of the Participant Panel and member of the NHS Genomic Medical Service People and Communities Forum  Lisa Beaton - member of the Participant Panel, panel member for the North East and Yorkshire GMSA and research and development for Harrogate Hospital Foundation Trust  Frances Allan – member of the Participant Panel and member of the following:  CRUK Women+s Cancers PPIE at Cambridge MHRA Yellowcard Biobank Northumberland NHS health forum Ovacome Healthforum IMPRESS cancer diagnostic tool study participant  You can find out more about the Participant Panel in our recent Genomics 101 episode which Lisa featured in, titled ‘What is the Participant Panel?', and you can read about their timeline of achievements over the last 10 years.   “One of the things as participants that we're always really keen to get across, particularly to the scientists, is that behind every piece of data is a face and a name”   You can download the transcript, or read it below. Sharon Jones: This time on Behind the Genes, we'll be celebrating the 10th anniversary of the Participant Panel, and we'll discuss how genomic research is being guided by patient and participant voices. The panel is made up of participants whose data is held in the National Genomic Research Library. They help us to put lived experience at the heart of our work. My name is Sharon Jones, and in this podcast we cover everything from cutting-edge research to real-life stories in genomic healthcare. Joining me this time are Kirsty Irvine, chair of the Participant Panel, and Frances Allan and Lisa Beaton, who are also both members. Collectively, they wear many hats for a range of organisations, which are listed in the episode description. As you'll hear, this one is all about people power. So back in 2016, the Participant Panel was in its infancy, with 12 founding members bringing lived experience of rare conditions. The idea was straightforward but radical: that the people whose genomes were being sequenced should have a real say in how the work was done. Over the decade since, the Panel has shaped some significant changes, from pushing for a service that let participants track their own samples, to publishing a language guide that changed how the genomics community talks about genetic conditions and disability. They've navigated the pandemic, welcomed new members and, in 2025, launched their first formal strategy. This year they mark their 10th anniversary, and today we're hearing from some of the people who've been part of that story. So welcome Kirsty, Frances and Lisa. So what was your reason for joining the Participant Panel? And I will ask Frances that. Frances Allan: Hi Sharon. I joined the Panel back in 2023 following a cancer diagnosis, and as part of that investigation I was fortunate enough to have a whole genome sequence performed. And they also asked would I be interested in taking part in a panel who look after this information, and I ticked the box and then thought no more of it. And then a month or so later I heard from the then Chair, Jillian, um, and had a chat about genomics and joined the Panel, and it was a very good decision that I made. Sharon Jones: Did you have any kind of expectations? What were your early thoughts when you kind of accepted? Frances Allan: Not many thoughts. So I was in the middle of my chemotherapy treatment, but one of the things that really stood out: when I signed the consent form, I said, well, of course I would do that. And the clinician consenting me, said, actually, not everybody does. And I thought, well, why would they not want to do that? So I was really interested in finding out about that. I had no idea how influential the Panel was, and that was great to discover as I became part of it. But seeing the breadth of the research and the knowledge already gained, compared to my rudimentary A-level Biology from many, many years ago, gave me incredible hope, um, and really helped me through a very difficult, difficult time. Sharon Jones: Yeah, that's, that's amazing. It's amazing that you could kind of think in that way whilst you were actually going through the treatment itself. I mean, how did you split yourself in that way? Frances Allan: I think it gave me a sense of, of purpose. So at the time, I'd, I'd stopped working to have my treatment and I was a, a vet previously, so I was used to thinking about medical things and problem solving, and it, it filled a, a void in my life. I had no idea I'd be able to contribute to it. I thought, well, I'd learn something from it. But, you know, the, the Panel is managed very well. Kirsty's a fantastic Chair. Everybody gets an opportunity to speak, and the attendance can be in person. And I've done most of them in person. When I was poorly I attended an online meeting, but even that is managed so well that you get a chance to speak up. If you're not feeling well enough, then you can, you can add it to the chat or email. So it's very, very inclusive and a very supportive environment, as well. Sharon Jones: Yeah, it sounds like a, a very safe space to be in. And Lisa, what was your reason for joining the Participant Panel? Lisa Beaton: I think it was sort of one of those, bit of a light bulb moment for me thinking, yeah, I could do that. I'm not quite sure why I felt I was qualified to do that, but my reasoning is slightly different than Frances. So I joined the 100,000 Genomes Project back in 2015 in respect of one of my children who has an undiagnosed, thought to be neuromuscular, syndrome. Um, so myself, my husband and our daughter recruited for genetic sampling, and over the years I've sort of taken a keen interest in all things genetic and genomic related, followed on kind of various social media platform. And I think if memory serves, I saw an announcement or an advert stating, do you want to be part of the Participant Panel, clicked on the link and thought, this is something that really resonates with me. I've served with different hats on different kind of participant groups and speaking events, and it's something I feel really, it's an overused phrase, but I do feel really passionate and strong about it because, you know, we are the people who are the front and centre of this, because it's our genetic information. So I applied, did a bit of a kind of resume of myself, um, then had huge imposter syndrome and thought, oh, that'll be the last I'll ever hear of that. And uh, actually had a really lovely interview with some of the then, uh, members of the Panel and must have said a few of the right things, 'cause here I am, three years down the line. Sharon Jones: That's amazing. Has it lived up to your expectation? How has it, how has it helped you get through what sounds like a really challenging time? Lisa Beaton: It's, it probably sounds wrong to say I, I didn't really have an expectation, but I joined it really just wanting to kind of know more and see if I could find out more details, more information, kind of more genomic discovery, and hope that I could give something back, if that doesn't sound too cringey. I think one of the things I'm always really keen to say is that you don't need to be a geneticist. You don't need to be a scientist. You don't need to kind of have lots of scientific information. And I will confess that the very first meeting I went to, I did come away thinking, I think I probably only understood about one word in three. But three years down line as I say, I'm still here, and it's been good to challenge myself and to explore kind of things that I don't know information about, but also I found that there are areas that I can definitely bring lived experience to and, and hopefully a voice for people like myself and my family. Sharon Jones: Yeah. That's so important. It sounds like you've become a bit of an expert by, uh, experience there. Has your vocabulary improved in the last three years? Do you know more words now? Lisa Beaton: Yes. Uh, I've, I have to remind myself not to use an acronym. It's one of my pet peeves. You know, when you're, you're in a, a meeting and terminology or, or vernacular, that is not necessarily something that people would use day-to-day, and I think lots of you know, you don't, don't have to be genomics or genetics to, um, using acronyms for things. It's something we all need to remind ourselves that just because you know that expression, somebody else doesn't. So it's really important to kind of keep that at a, a lay explanation so that everybody understands it. Um, I think particularly with quite heavy subject matter such as genomics and genetics, there can be a tendency otherwise for people to feel that it's not for them. And of course it is, because it's about our own personal data. Sharon Jones: Yeah, absolutely. And, um, and coming to you, Kirsty, what were your kind of motivations for, for joining the Participant Panel? Kirsty Irvine: Well, it's been quite a long journey for me to find myself on the Participant Panel, so I and my family, we were all consented into the a 100,000 Genomes Project back in 2015. But from that point, I then spent nearly 10 years chairing committees at NHS Digital and then NHS England, focusing on health data access. And I remember talking about the 100,000 Genomes Project at my interviews for those roles. I then went down a different path. And in those roles I was very much wearing my solicitor's hat. So I was thinking about governance and risk and were we complying with the precise wording of the legislation. And then when the chair role came available, I had a number of people sort of forward it to me saying, I think this would suit you. I think this would suit you. And at that stage, I was aware of the Panel because I'd met the fantastic former chair, Jillian. Um, so I'd seen Jillian at various conferences and meetings and things, so I was well aware of what the Panel did. I was well aware of the Panel's standing. It was probably the only participant panel that I was aware of in my work with NHS Digital, NHS England. And then I realised, you know, I wanted to be closer to the people behind the data and I wanted to do something more active. I wanted to bring a bit more of myself. Because when you're chairing a very formal committee, at NHS England, you, you can't talk about the time that you resuscitated your child at home, you know? And on the Panel, you know, my very first meeting, I, I met someone, someone whose child had, you know, been fed with an NG tube for a number of months. You know, I met someone else who had resuscitated their child, you know, and all of a sudden I could bring more of myself to my colleagues and, and find a real community. So for me, joining the participant panel was a way of shifting the perspective, but to also bring that experience with me because I, the roles at NHS England, you know, from a governance perspective, I couldn't continue chairing those, you know, board subcommittees forever. But I didn't want that knowledge to just sort of disappear. So for me, I'm really delighted that I've, what I hope, what I hope is a good fit. I feel it's a good fit. So that, that's been my journey to the Panel. Sharon Jones: Yeah, that's, that's so interesting. And I guess having that space to kind of be yourself, and having understanding because of your lived experience, brings a lot of value to the role that you're doing now in a way that kind of is different when you're in your previous roles of NHS Digital, because you had to be a bit more, kind of stand back from it and, yeah. That's so interesting. So, what has it been like being part of these groups? You know, the ones that you kind of, you're involved in a lot of things, and we'll list them in the, in the web description. And how has it kind of affected your life, essentially, because it's not the kind of average thing that people are involved in. Frances Allan: So it's been an incredible, I think as Lisa alluded to, incredible learning curve. We've learnt so much. But the team at Genomics England are endlessly patient and very skilful at passing that information on. And we have access to the leading researchers, the clinicians that are involved in genomics. And they're happy to take any question. And the questions, however silly, there's no silly question. They're happy to answer that. And so we learn every time we attend a meeting, we have quarterly meetings and that can be in person or online. Um, but we also have regular lunch-and-learns. So if there's somebody we want to speak to or find more about their specialist area, they'll come and have a, a chat with us. And then we have half of it, them chatting to us and half us, us. Us asking them questions and, and challenging them. Um, so it's very, very informative and then learning from each other. And as Kirsty was saying, you know, this is a, a group of people who've, who've dealt with an awful lot of unique situations and they're happy to, to share that and pass on the information. It's a, it's a great place of learning. Sharon Jones: Lisa, would you agree with that? How it been for you? Lisa Beaton: Yeah, I would definitely echo everything that Frances has actually said there, and I think it's a very humbling experience, as well. Ostensibly, we are a, a collection of individuals who have all been brought together, um, purely because of, uh, our genomic interests. And whether that's for our families, you know, as, as parents, as in my case, or in somebody like Frances' case, who's obviously a participant in her, in her own right. And although there are kind of many differences in our stories, there's also a lot of similarities. But I think what's really interesting, very precious, is that the staff at Genomics England, obviously they range from, you know, there, there's so many different kind of areas from the, the comms, the scientists, etc., but everybody is really interested. They want to know your story, who you are, why you are there. There's a real kind of inclusion focus on that. And one of the things as participants that we're always really keen to get across, particularly to the scientists, is that, you know, behind every piece of data is a face and a name. And I think they really make that felt when they're chatting to us. You know, we go in and, and there, there's people who are there from governance sides for how the data is accessed by other parties. There's people there who are the science technicians, etc. There's people who are dealing with the administrative side of things, but every single person that I've encountered wants to know more about you, what you are there for. And that is, is very, very precious. And as Kirsty also alluded to, a lot of us have been through some really quite traumatic experiences. It, it's not my place to speak of others' journeys, but you know, there, there are, uh, bereaved parents and family members among us. And so we are sharing very precious raw material, emotions, experiences, and that is very powerful, as well. And I, I think the Genomics England staff never forget that. They seem to bear that at the forefront of their, their communications with us, always. Um, and certainly Kirsty and Adam and previous chairs, uh, of the panel, that inclusivity was entirely throughout every dealing we had with them. Sharon Jones: It's very humanising and I think that it's humbling for us who work here that that's always at the forefront of our mind, that this is why we kind of get up and go to work every day, because of that human element. And it's not just a data point. There is a whole family, a story, a history, and that's, that's so important to us in the work that we do. Kirsty, did you want to add your point on this as well? Kirsty Irvine: I've probably got two points I wanted to raise. One was just to draw out what Lisa was saying, is that it can be complex being a Panel member, because the story you're bringing often isn't just your own. In my family, we've got a real, we've got a whole range of genetic differences and conditions that, you know, across the extended family. And so when I speak, I'm often drawing on experiences that aren't solely mine to share, and, you know. So I think that's something that for some on the Panel, we're sort of, we're, we're being quite careful to think about what we're saying, and if we're speaking in the public domain, we might be talking about it in more general terms. So that's, you know, but there's not a single right way, and there's room on the Panel, everyone, for the people who can and, and as Lisa talked about, you know, the, the most acute situation is where someone's bereaved, you know. And it's, so everyone's got different, you know, different experiences. But that, that, again, coming back to the positive side of things, one of the biggest things to me about being on the Panel, what it means to me, is being part of a wider community. I mean, one of the other things that, Sharon, I don't know if I can sort of segue onto this about, you know, the opportunities that have arisen? Sharon Jones: Yeah, absolutely. I'd love to hear more about that. Kirsty Irvine: So one thing that really stands out for me was the opportunity to speak directly with, um, Associate Health Minister Ahmed about, and his policy team. So we went to the department, Adam and I went to the Department of Health, and it was about the use of GP data in consented research cohorts. So getting the GP data into the National Genomic Research Library. So even though there's consent, up until now, that GP data, that tranche of really rich data, hasn't, hasn't gone into the NGRL. So I'll use that abbreviation now that I've used it in full. And so what was really unique for me was that I'd seen it from multiple angles because I'm participant in the 100,000 Genomes Project, so I'm a cohort member. I then worked on the consent review for NHS England. I then sat on a, the consent review assessment committee with, you know, a multiparty group. And then, because I was on the panel, I got to see things full circle. I was then invited to, to go and meet with, um, Minister Ahmed and, and advocate for the use of this GP data. And that really matters because something, you know, there's such important information sitting in that GP data and it wasn't a given, it was not a given that the government was going to the direction that allowed that data to go into the NGRL. And so we were able to talk about how we really wanted that data to be used. And now, going forward, you know, something as simple as BMI or for example, if a, if an individual's coded for a neuro, neurodevelopmental condition like autism, sometimes that data actually only sits in the GP health record. It's in primary care only, so it's not necessarily in the hospital records or other records. And so this is really, really valuable data for, for researchers. And so that was something that was a really special experience, just being able to see that come full circle. And I felt like it's a really tangible example of how the participant voices really helped strengthen that conversation, you know, with the DH policy team, you know, and the government ministers. Sharon Jones: Yeah, I mean that's, that's really powerful and it, it just sort of shows how these opportunities can arise from being involved in a participant panel in a way that you wouldn't have necessarily had that power if you hadn't been involved. And you know, obviously you are wearing lots of different hats in that, in that position, Kirsty. And um, it just sort of shows what can be done when you're, unfortunately, you know, you're in this group for a reason and it's not necessarily the, the most cheeriest reasons, but it, you still leverage that opportunity to create something positive, you know, with it. Frances Allan: So we've given all sorts of opportunities and we seek to get involved with as many things as we can to speak and have our voice heard. Um, and one of the things I did last year was, um, do a short presentation to open a stage at the Genomics England Research Summit, which was quite a challenge for me, but I felt very exhilarated having done it. And then a couple of people came up afterwards and just said, oh, thank you for sharing your story. And a researcher who was slightly older than I, so very experienced, been in his field a long, long time, and he said his clinical years were long behind him, and now he researches within a lab. And actually for someone to say, you know, thank you for, for looking, thank you for finding, had a very profound experience on him. And he knew there was a clinical benefit; his research was very clinically led. But he said he hadn't thought about the recipients of those findings. And I pointed out every time you have that chat with somebody, come to an event like that, have a network, spend a bit longer in the lab, look for something that you might not find, even if it's a negative finding, there will be somebody eventually that benefits from that. And I've been a direct recipient of other people putting forward their whole genome sequence, and then a common change was noted in people with the type of cancer that I have, and that then qualified me for a treatment that otherwise I wouldn't have been eligible for, and I wouldn't have been, I wouldn't have been here now. So it's a very, you know, profound thanks to all the people that are involved from everybody within Genomics England, all the researchers, all the other patients that speak up. We each have a contribution to make. Sharon Jones: Yeah, that's amazing. That must have been quite a poignant experience when you, you met him at the, um, Summit, of just kind of the other side of the, the world that you don't often see. And they obviously don't see our side of the world, and it's kind of interesting to join those dots and kind of come full circle. So moving on. In terms of like, collectively, there's a lot of impact that you have and there's a noticeable shift in organisations where people with lived experience are playing, you know, a much bigger role in decision making. Can you help our listeners understand how people are getting involved in governance and shaping research? Lisa Beaton: From my perspective, it comes back to that word "embedding". I think historically, perhaps there's been an, an almost about-face. Um, it's kind of come at it very backwards, that that embedding has almost happened as an afterthought, which is sort of a bit of a misnomer way of explaining it. When you're talking about embedding, obviously it should be the foundation. Historically, at least both from the parent, parental perspective, I've seen that with clinicians, for example, that historically I've been made perhaps to feel a bit of a thorn in someone's side, that even though we're there for an appointment about our young person, when I'm asking questions that they don't necessarily want to answer, you know, I'm almost the, the add-on rather than the reason that we're there. And I think there has been a paradigm shift in everybody's approach to that. So thinking much more about, you know, the, the what's, the wherefores, the whys. How do we ensure that right from the get go, that patient or participant voice is heard, and it shapes the question. And one of our other Panel members frequently uses the phrase, "nothing about us without us", because that is front and centre of why, you know, genomics exists in the first place, really. Without that data, the conversation ceased to exist. It, it's so vitally important, not just for us as an individual, not just for our family members, but for the greater good, if that doesn't sound too grandiose. Sharon Jones: No, not at all. And, and, and Frances? Frances Allan: I think having raised that value of patient advocacy: what we have to say. So it started off, people felt that they should have some, so they included it, but actually once they started to include it, they thought, this does contribute to our study. And starting at the very beginning of the research project, so what is reasonable to ask participants and patients to do? Is it something that there is benefit from? And trying to see that end goal right at the beginning. And we might help shape a research study that actually goes in a beneficial direction, rather than the researchers starting alone, and then actually getting into the study, and the procedure is, is too painful to endure, there's no clinical benefit, it's not something that can be translated into clinical practice, and it gets abandoned. So start us right at the very beginning, and our perspectives may not be what, what researchers or clinicians think. Uh, with that lived experience, however empathetic you are, the lived experience is a very unique lens and position to look from. Sharon Jones: Yeah, it absolutely is. So, given that you are part of a small group and you know, you're representing a much wider community, essentially, like, what are the considerations that you, you have to bear in mind? Lisa Beaton: I think we can only speak, obviously, to our own individual experience and we are very aware that, you know, diversity, ethnicity, inclusion is something that is a much bigger conversation and certainly something that we want to broaden in, in the panel itself. And I know there's kind of lots of work and thought going into how that can widen those perhaps more diverse communities that historically... It's not that, there's, there's been a terminology that, you know, they're difficult to access, but actually the question is wrong there. The statement is wrong. It's not that they're difficult to access, it's just that we've been asking that incorrectly. And we need to ensure that they are, uh, empowered to bring their stories forward and find ways to push forward for their inclusion. We need to ensure that everybody's voices are heard, otherwise the data set is wrong from the off. So I think that's something that we're all very minded when we speak about, and definitely want to, to diversify the pools of data that come in. That, that has huge resonance for, you know, shaping genomic and genetic policies moving forward, for sure. Sharon Jones: Yeah, definitely. Frances, sort of broadening out that question. Does it feel like a lot of pressure and a lot of responsibility, kind of representing, you know, in this kind of small group where you are almost speaking on behalf of, you know, a lot of people? Frances Allan: I think it mainly feels like a, a privilege, Sharon, to be in that position, to have a say. And back to my, one of my motivators for joining is why would people not choose to do this? And actually understanding why that is. And is it the, you know, the lack of knowledge of genomics? And there is a lot of, of fear about what can be discovered. But understanding the immense benefits from that so people don't miss out on those opportunities. Our genomes contain the, the blueprint to us, but also how we would respond in certain situations, and you want everybody to be using those leverage points. You know, cancer's a really difficult disease to manage, and anything you can do to make it slightly easier, slightly more comfortable, slightly more successful, we want to do that. So every time we speak out and we advocate for the benefits of genomics, we might gain one more person who's going to feel that a successful outcome. Sharon Jones: Yeah, and who knows what, what that can mean for their family and, and sort of further down the line. So have you got any advice for, or encouragement, or any tips for, you know, potential participants who are thinking of getting involved in, in groups? You know, it doesn't necessarily mean the Participant Panel, but just generally, sort of groups related to their conditions or their family's conditions. Frances Allan: Yeah, I think the value of the one's personal experience: don't underestimate that. Everybody has an individual journey and they can comment and reflect on that. And anybody interested in, in joining our panel, you can include in the, the copy or description, ways they're getting in touch with us and speak to us about what that, what that involves. And uh, Lisa said at the, the beginning, you come and it's a huge learning curve, but there are people to support you and guide you through that way. And the learning is, is just fascinating. And there's a position for everybody and everybody's point of view to be heard, and you will be heard. Sharon Jones: Thank you. Lisa? Lisa Beaton: Yeah, I think I might steal a phrase or two actually from some, uh, well-known brands. But, um, one would be "just do it" and the other would be "feel the fear and do it anyway" because, you know, you are amongst friends, first and foremost. We all, we do tailor our experiences, and clearly we self-censor at times because that's necessary to protect the privacy and dignity of not necessarily ourselves, but as we've already alluded to in our chats, but you know, our family members, the wider people that you are aware will be hearing this. And you don't necessarily want certain medical information about your family members out there, because it's not your information to share. But in terms of joining the panel and, you know, having a voice, giving more voices, giving more diverse data, we, we need as many people as possible to come. We need more voices. We need to get our genetic, genomic information out there, uh, in front of the researchers and, and all involved with Genomics England, um, and other patient advocacy groups, as well, because that will only benefit the greater public. Sharon Jones: Thank you. And Kirsty? Kirsty Irvine: I'm just thinking about sort of general tips building on what Lisa and Frances have said. You don't need to be a seasoned public speaker. I think that's something, absolutely not. We've got some fantastic speakers in the group. Um, but then we've got people in the group who've got, who have got different skills, so don't think that you need to be ready to give a TED Talk at the first meeting, be that the Participant Panel or whatever group you might be motivated to join. We, we just need good listeners. I've chaired meetings in the past where people, uh, wanted to contribute via the chat function, and that worked absolutely fine. They would put their incredibly insightful, erudite comments in the chat, and then I would relay them to the group, and that was how we got that person's input, because we realised that they weren't necessarily going to speak up in the forum. So whatever your communication style, we can accommodate it at the Participant Panel and we would be delighted to hear from you. Sharon Jones: That's great. Thank you. Um, final question. So what do you hope the next 10 years of participant involvement will look like? Kirsty Irvine: I think if I could use a little catchphrase, which I'm sure is not mine, but I would like to see us fully integrated as partners, not participants. I'll put that out there. I mean, Sharon, I wonder if I could sort of also open things up to how are things going to look in another 10 years, because there's been some statistics that have really struck me, uh, at presentations that, that we've heard. One of them being that in the next, you know, within 10 years, around about half the data in the National Genomics Research Library will be from, I don't know if this is the best name for it, the general population. So that's people who aren't necessarily seeking an answer, or have a diagnosis or a condition. These are people who have donated their genomic data through being part of, you know, research projects. And, as a panel, so Genomics England's evolving and the panel will be evolving. And in 10 years time, the panel will need to be, I believe, true to the original route. So, 100,000 Genomes Project. Uh, the people who've had their whole genome sequencing through cancer diagnoses. You know, there's a significant COVID cohort, but also people of the gen, general population. So how do we advocate for and look after everyone in that broad group of people. So I think that, that's both a challenge, that's a challenge for us, but it's also really exciting to think how we can meet that challenge. Sharon Jones: Yeah, definitely one, definitely an opportunity and a challenge, and one that will take a lot of thinking in the next few years. Frances? Frances Allan: Yeah, thanks Sharon. I think looking forward to that, that 10-year period is how genomics just becomes a normal part of everybody's healthcare, so we all fully understand the benefits of it. People are willing to participate in it and then using lots of different types of data to go into the National Genomics Research Library. So at the moment, it's mainly genomics material, but there's been a lot of work done with the cancer cohort, putting in diagnostic images, pathology slides, other clinical data, written notes, and this can then be accessed under the strict criteria of the access review committee. It can be accessed by clinicians, researchers across the world. And we want our research library to be the premium source of that information and to have collaboration with researchers, clinicians, participants, worldwide, to speed up the generation of that information and those positive outcomes. It's a, a very, very rich data source now, and it'll only get bigger as we include people from the general population. Sharon Jones: That'd be amazing and have some quite incredible global, um, outcomes. Lisa? Lisa Beaton: I just had a little image actually pop into my head that I, I almost look at it a little bit like we're doing one of those, I think they might be called an "impossipuzzle" where actually we don't have the picture on the box, but we have lots and lots of little pieces that are all going in together and they're making up a really creative, wonderful, fantastic, woven story, a tapestry as you were, of different information that's coming through. And how incredible, you know what, what a wonderful legacy we're building, you know, and this amazing picture that's going to evolve and change and develop over the years to come. Sharon Jones: That's a wonderful note to end on, so we're going to wrap it up there. Thank you for listening. A special thanks to our guests, Kirsty, Frances, and Lisa, for joining me today as we discussed how lived experience can shape health research. If you'd like to hear more like this, please subscribe to the Behind the Genes on your favourite podcast app. And if you want to know more about the Participant Panel, you can head to the Genomics England website and listen to our 10-minute explainer podcast, Genomics 101. Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan and Dave Howard at Bespoken Media.

Drew Flugstad-Clarke never planned to work in brain cancer. She planned to play Division I soccer at Georgetown. She planned to paint. She even tried investment banking, answering emails at 4am in a cubicle that never slept. Then in June 2022 her father, Jim, was diagnosed with glioblastoma at 57. He died 1 day shy of 7 months later, just before his 58th birthday. His symptoms began with emotion, not seizures. A steady HR executive suddenly cried. His golf game slipped. By the time he entered the hospital for a scan, he did not leave without surgery. A subway poster for a 5K became a lifeline. Drew showed up. She found a community. She later joined the American Brain Tumor Association as Community Manager for the Eastern Region. This conversation walks through anticipatory grief, caregiving in real time, strategic numbness, and what it costs to curate hope when the median survival clock is already ticking.RELATED LINKSDrew Clark Flukestad on LinkedInTopor StudiosAmerican Brain Tumor AssociationGeorgetown University Women's SoccerFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

You'd never ignore your interest rate, so why aren't you tracking your genetic gain? This week, Ferg catches up with Chad Taylor for an update on what has been happening at Mumblebone and the recent work around footrot and feet structure they have been involved with as part of the 'Genetics of foot health in Merinos' project.Ferg and Chad also discuss genetic gain at Mumblebone and how it is being pushed in practical terms. For example they are using ram lambs more heavily, joining ewe lambs, using genomics and utilising custom indexes in selection decisions. Chad also explains why genetic gain should be tracked and questioned just as closely as interest rates, because both compound over time and have a direct impact on the long-term performance of the business.Finally, Ferg and Chad discuss what supports all the progress they're making on-farm. Chad is very keen on building the right team and aligning people with the direction of the business, and he shares the impact of bringing staff into the bigger picture by "opening the books" so they know how the business operates financially.It's always a pleasure to have Chad on the podcast. Tune in to hear a top operator's approach to breeding great sheep. Links:Precision Sheep HQ: https://www.precisionsheephq.com/feed'Genetics of foot health in Merinos' project cull ram challenge: Email amy@nextgenagri.comMineral basics for healthier stock and higher returns: https://thehub.nextgenagri.com/c/events/mineral-basics-for-healthier-stock-and-higher-returnsHead Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, Heiniger Australia and New Zealand, and ProWay Livestock Equipment. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out the MSD range HERECheck out Allflex products HERECheck out Heiniger's product range HERECheck out ProWay's product range HERE

In this episode, Dr. Aly-Khan Lalani, Dr. Christopher Wallis, and Dr. Alex Wyatt walk through the fundamentals of clinical genomics and why it matters for routine practice. They discuss which alterations matter in prostate cancer, germline vs. somatic testing, ctDNA test use cases and limits, and more.Dr. Alex Wyatt is an Associate Professor in Urologic Sciences and holds the President's Excellence Chair in Precision Oncology at the University of British Columbia. He is also a Senior Scientist at the Vancouver Prostate Centre and BC Cancer, where his work focuses on advancing clinical genomics and precision oncology in prostate cancer.This podcast has been made possible through unrestricted financial support by Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

Janine Durso spent 30 years inside pharmaceutical advertising shaping healthcare narratives before becoming a belief strategist and founder of The Believist. In November 2024, during a routine Zoom coaching session, she felt what she called a sharp, terrible pain in the right side of her head. Within hours she was in surgery for a ruptured brain aneurysm. She does not remember the ambulance, the ICU, or the first weeks that followed. She spent 5 weeks in intensive care, then 10 days relearning how to walk, calculate simple change, and manage basic cognition. Doctors later placed a stent and continue monitoring a second unruptured aneurysm.This episode traces the moment she told her husband something broke in my brain, the 14 days doctors called touch and go, and the slow mental rebuild that followed. It also examines insurance barriers that require 2 direct relatives with aneurysms before screening coverage, and why she now lobbies in Washington for change.RELATED LINKSJanine DursoThe BelievistBrain Aneurysm FoundationWhite Plains HospitalDr. Jared CooperFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In Pomegranate we go back to some classic episodes from the last ten years that have stood the test of time. The first throwback takes us back to 2017 with episodes 20 and 21 titled “Genomics for the Generalist.” While there's been a flood of genomic discoveries since this story was first published, it's still a good primer on fundamental concepts and everyday challenges for the physician advising a patient. The expert guests include a genetic pathologist, a clinical geneticist, a genetic counsellor and a medical oncologist. The podcast covers the different roles for single gene tests and whole genome sequencing, which has become much more accessible. We tackle question of disease risk and how to present uncertain predictive diagnoses to consumers. This is particularly relevant to using genome-wide association studies, which re finding more and more markers with very small associated risks of disease. This increases the likelihood of picking up diagnoses incidental to the ones a clinician might be looking for. The ethics of consenting patients to genome screening and informing them of incidental findings are also discussed. Chapters3:04 Mendelian vs multi-gene diseases6:42 Whole genome sequencing10:09 Prenatal testing12:38 What do physicians need to know? 17:07 Pharmacogenomics19:52 Genetic counselling22:40 Funding of genetic tests33:46 Incidental findings39:13 Consent and privacy issuesGuests (2026 affiliations)Professor Leslie Burnett FRCPA, FHGSA, FCAP (University of New South Wales; Virtus Health) Professor Michael Gabbett FRACP (Queensland University of Technolgy; Mendel Genetics) Associate Professor Kristine Barlowe-Stewart FHGSA (University of Sydney; Children's Cancer Institute) Prof David Thomas FRACP PhD (University of New South Wales; Omico)ProductionProduced by Mic Cavazzini DPhil. Music courtesy of FreeMusicArchive includes, 'Cloud Line' by Blue Dot Sessions, 'Is That You or Are You You?' by Chris Zabriskie, First Holes' by Cory Gray, ‘Brand New World' by Kai Engel. Music licenced from Epidemic Sound includes ‘Abyss' by Luwaks. Image customised for RACP. Editorial feedback for 2017 podcast provided by members of the podcast editorial group Dr Pavan Chandrala, Dr Tessa Davis, Dr Rebecca Grainger, Dr Michael Herd, Dr Paul Jauncey, Dr Joseph Lee, Dr Marion Leighton, Dr Anutosh Shee and Dr Ellen Taylor, and Advanced Trainee Dr Katrina Gibson.Add educational activity to MyCPD as educational activity or visit web page for a transcript and references. 

Genomics of the Golden Horde Science Sessions are brief conversations with cutting-edge researchers, National Academy members, and policymakers as they discuss topics relevant to today's scientific community. Learn the behind-the-scenes story of work published in the Proceedings of the National Academy of Sciences (PNAS), plus a broad range of scientific news about discoveries that affect the world around us. In this episode, Ayken Askapuli explains genomic insights into the ancestors and descendants of the Golden Horde. In this episode, we cover: •[00:00] Introduction. •[00:56] Population geneticist Ayken Askapuli introduces the Golden Horde. •[02:01] He describes the individuals in the mausoleums whose DNA the team sampled.  •[04:11] Askapuli explains findings about the modern populations the Golden Horde individuals were related to. •[05:08] He then explains findings about the Y chromosome characteristics of the Golden Horde individuals. •[06:14] Askapuli talks about what the results say about the ancestry of the Golden Horde. •[06:48] He describes how the results aid understanding of population genetics in central Eurasia. •[08:10] He lists the caveats and limitations of the study. •[09:53] Conclusion. About Our Guest: Ayken Askapuli PhD candidate University of Wisconsin-Madison View related content here: https://www.pnas.org/doi/abs/10.1073/pnas.2531003123 Follow us on Spotify, Apple Podcasts, or wherever you get your podcasts for more captivating discussions on scientific breakthroughs! Visit Science Sessions on PNAS.org: https://www.pnas.org/about/science-sessions-podcast  Follow PNAS: Twitter/X Facebook LinkedIn YouTube Sign up for the PNAS Highlights newsletter

Send us Fan MailA cancer diagnosis doesn't have to feel like a death sentence. The science is advancing faster than most people realize, and what patients know about their own diagnosis can change everything.Dr. Sanjay Juneja, TheOncDoc joins host John Driscoll to discuss why cancer is increasingly a manageable disease, how patient empowerment and early detection are shifting outcomes, and what everyone can do right now to reduce their cancer risk.

Guest Alan Rubin Panelist Richard Littauer Show Notes On this episode of Sustain, Richard Littauer sits down with computational biologist Alan Rubin to explore how open source software supports scientific research, clinical genetics, and cancer-related data infrastructure. Their conversation centers on MaveDB, a project that began as a way to organize hard-to-find variant data from research papers and has since evolved into a valuable resource for both scientists and clinicians. Along the way, they discuss infrastructure funding, research software sustainability, and why open source communities and academic researchers have a lot to learn from each other. Press download now to hear more! [00:01:24] Alan explains his role leading a research group focused on genomics, cancer medicine, and improving patient care through genetics. [00:02:46] We learn more about what MaveDB does. [00:06:52] Alan details why a database was needed. [00:08:26] Alan shares how the project grew out of collaboration, PyCon AU inspiration, Django, and Python tooling that let a small team build a practical research database. [00:11:54] There's a discussion on the infrastructure funding problem and Alan explains a major theme is how hard it is to fund scientific infrastructure, since most grants favor new discoveries rather than maintaining shared tools and databases. [00:17:55] The project took a major turn when clinical geneticists began using the data to interpret patient variants, pushing the team to rethink the interface and user needs. [00:21:13] Alan describes the new clinical-facing interface, Mave for Medicine (MaveMD), designed to help doctors evaluate specific variants for diagnosis and treatment decisions. [00:22:02] Alan talks about managing the project through a distributed team, shared responsibilities, and a role that now centers more on direction, priorities, and community than day-to-day coding. [00:23:36] They discuss why research software rarely attracts hobbyist contributors, even when the mission is compelling, and how scientific projects often function more like small product teams. [00:27:44] Alan makes the case that scientists often learn more about improving their software craft at events like PyCon than at discipline-specific conferences. [00:30:38] Alan highlights how academic software depends heavily on mature, well-documented open source tools and encourages more connection between technical communities and scientific work. [00:34:15] Find out where you can learn more about MaveDB and Alan's work. Quotes [00:10:04] “We quite literally followed the Django Girls tutorial, but instead of a building a blog, we built a database for research scientists.” [00:12:35] “Infrastructure is something everybody wants to have it exist and nobody wants to pay for.” [00:26:08] “I have never been successful in engaging the broader open source community, despite having tried many times to contribute to this or any other scientific project.” [00:31:01] “I think people who work in OSS should be excited about the kind of stuff that their work is enabling, even if they don't really hear about it.” Spotlight [00:35:44] Richard's spotlight is the book, News of the Dead. [00:36:22] Alan's spotlight is The Global Alliance for Genomics & Health (GA4GH) and all the good work they're doing. Links SustainOSS podcast@sustainoss.org richard@sustainoss.org SustainOSS Discourse SustainOSS Mastodon SustainOSS Bluesky SustainOSS LinkedIn Open Collective-SustainOSS (Contribute) Richard Littauer Socials Alan Rubin LinkedIn Dr. Alan Rubin Website (The University of Melbourne) PyCon AU 2026, Brisbane, August 26-30 Sustain Podcast- Episode 286: Jack Skinner of PyCon AU and Regional Confs Sustain Podcast- Episode 176: Maintainer Month with Russell Keith-Magee & Uriel Ofir Django Girls PyCon AU 2023-“Building a biological database with Python”- Alan Rubin (YouTube) Sustain Podcast- Episode 135: Tracy Hinds on Node.js's CommComm and PMs in Open Source Sustain Podcast-Episode 190: Karen Sandler on Software Freedom Conservancy (SFC) Original database paper (Pub Med) Database update paper (Pub Med) Preprint on the clinician-oriented interface Variant scoring tools for deep mutational scanning (Pub Med) Atlas of Variant Effects MaveDB News of the Dead Global Alliance for Geonomics & Health (GA4GH) Sponsor CURIOSS Credits Produced by Richard Littauer Edited by Paul M. Bahr at Peachtree Sound Show notes by DeAnn Bahr Peachtree Sound Special Guest: Alan Rubin.

Send us Fan MailWhy does it take five years to diagnose a child with a genetic disease when the answer is available in 48 hours?In this clip from our episode “How Genomics Is Transforming Rare Disease Care”, host John Driscoll and guest Katherine Stueland, CEO of GeneDx, expose one of the most frustrating gaps in pediatric medicine today.

With more than 30 years of experience in health disparities research, Mr. Vence Bonham, president and CEO of Meharry Medical College's Diaspora Human Genomics Institute (DHGI), joins Dr. James E.K. Hildreth to explain how genomics is shaping the future of personalized medicine, and why the lack of diversity in genetic data creates major gaps in care. Through initiatives like Together for Change, Meharry is working to build one of the largest genomics databases of individuals of African ancestry, reshaping and improving treatment, screening and health outcomes for generations to come.  

Rebecca Benghiat holds a JD, passed the bar, and skipped corporate law to build mental health systems instead. She now serves as Chief of Staff and Head of Impact at Inner Foundation, where she helps direct capital toward emerging adults ages 18 to 30 and asks a hard question every day: Is this actually working?In this conversation, she dismantles the myth of easy fixes. She explains why mental health measurement resists clean metrics, why a PHQ 9 score starts a conversation but never finishes one, and why “scale” often flatters institutions more than it helps people. She breaks down how impact investing shapes care delivery, why schools need networked systems not slogans, and why friction might be developmentally necessary.The stakes are real. Vulnerable families navigate snake oil, glossy apps, and pay to play algorithms while carrying the burden of choice in crisis. Benghiat lives inside that complexity and refuses to simplify it.RELATED LINKSRebecca BenghiatInner FoundationAspen Ideas HealthThe Jed FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Why He Can't Stop: The Truth About Porn Addiction, Cheating & Compulsive Behavior in Relationships You keep asking the same question: Why does he keep doing this—even when he knows it hurts me? In this eye-opening episode, Lora sits down with former Buddhist monk and addiction expert Jeremy Lipkowitz to unpack the real reasons behind compulsive behaviors like porn use, cheating, and addiction. This conversation goes far beyond surface-level answers. Together, they explore how addictive behaviors form, why they aren't about you, and what true recovery actually requires. If you've ever felt confused, hurt, or stuck trying to understand your partner's behavior—this episode will bring clarity, validation, and a new way forward. Top 3 Takeaways It's not about you—it's a coping mechanism. Most addictive behaviors begin early and are rooted in emotional regulation, not love, attraction, or relationship satisfaction. Addiction is about pain, not pleasure. The real question isn't “Why the addiction?”—it's “What pain is being avoided?” Healing requires addressing the root, not just stopping the behavior. You can't shame someone into change—but you can create awareness. True transformation happens through self-awareness, accountability, and building a life that no longer needs escape. Pull Quotes "Addiction isn't about wanting more pleasure—it's about trying to escape a life that doesn't feel good.” About Jeremy Jeremy Lipkowitz is a former Buddhist monk, meditation teacher, and ICF-certified executive coach who helps high-achieving men break free from compulsive behaviors—especially porn addiction—and build lives of integrity, discipline, and deep fulfillment. With over 13 years of meditation experience and hundreds of days spent in silent retreat, Jeremy blends ancient wisdom with cutting-edge science to guide individuals toward emotional resilience and personal freedom. A former genetic researcher who earned Bachelor's and Master's degrees in Genetics & Genomics and pursued a PhD at Duke University, Jeremy left academia after confronting his own struggles with addiction, shame, and self-judgment. A brief period of monastic training in Myanmar deepened his mindfulness practice and marked the start of a lifelong commitment to personal growth and service. As the founder of Unhooked Academy and host of the Unhooked Podcast, Jeremy is a leading voice in destigmatizing porn addiction and educating the public on effective, science-based recovery strategies. His work helps men overcome shame, understand the neuroscience of addiction, and create lasting transformation through mindfulness, emotional intelligence, and habit change. For over a decade, Jeremy has taught at universities, recovery centers, and global companies across the U.S. and Asia. His calm, grounded presence and ability to bridge analytical thinking with inner work make him a sought-after guide for professionals and executives looking to reclaim their lives from digital distractions and self-sabotaging patterns. Credentials & Training: CPCC, Co-Active Training Institute ACC, International Coaching Federation (ICF) Certified Teacher, Search Inside Yourself Leadership Institute (SIYLI – developed at Google) The Turning Point After years of outward success—academic achievements, career accomplishments, and global recognition—I still felt a deep sense of emptiness and disconnection. Behind the polished exterior, I was battling a compulsive porn habit, struggling with shame, and silently wondering what was wrong with me. Eventually, I hit a breaking point. I left my PhD program, became a Buddhist monk, and began a deep inner journey of healing and transformation. Now, as a mindfulness-based executive coach and founder of Unhooked Academy, I help high-achieving men reclaim their focus, integrity, and sense of self. Together, we replace shame with clarity, and compulsive behaviors with purpose-driven action. Learn More at www.UnhookedAcademy.com LOVE THE SHOW? TAKE THE NEXT STEP Don't just listen—start healing. Get your free downloadable guide on the “The Top Three Ways You Betray Yourself Every Day, and How to Stop” at www.burnoutorbetrayal.com. https://workplace-burnout.com/the-top-3-ways-you-betray-yourself-every-day-and-how-to-stop/ If you're ready to Rise Up & Reign as the creator and queen of your life, let's talk. I will walk by your side and give you the perspective, permission, and wisdom needed to turn your betrayal experience into something constructive, empowering, and transformative in all the right ways.  Learn more at www.loracheadle.com and follow me across all social! Download your Sparkle After Betrayal Recovery Guide at www.BetrayalRecoveryGuide.com, a guide designed to help you take the first steps in feeling better, so you can reclaim your power, own your worth, and start putting yourself, and your life, back together again. About Lora: Lora Cheadle, JD, CHt is a betrayal recovery coach, attorney, TEDx speaker, and author of FLAUNT! and It's Not Burnout, It's Betrayal. After uncovering her husband's 15-year affair, she turned her own pain into purpose—helping high-achieving women reclaim their identity, power, and joy. A trauma-aware coach, somatic therapist, and former attorney, Lora blends legal insight with emotional and spiritual healing for full-spectrum recovery. She is the author of FLAUNT! Drop Your Cover and Reveal Your Smart, Sexy, & Spiritual Self (an International Book Awards Finalist and Tattered Cover Bestseller) and It's Not Burnout, It's Betrayal: 5 Tools to FUEL UP & Thrive. She also hosts the podcast FLAUNT! Create a Life You Love After Infidelity and Betrayal. Learn more at www.loracheadle.com and follow me across all social! Get the support you need to find your footing, begin making sense of it all, and feel better fast. As an attorney, betrayal recovery expert, and survivor of infidelity I can help you find the clarity and confidence to create a life that you love on the other side of betrayal. Book Your Session Here: https://calendly.com/loras-schedule/coaching-session Thank you to BetterHelp for sponsoring this podcast! Take charge of your mental health and get 10% off your first month of therapy at https://BetterHelp.com/FLAUNT  READY TO START A BETTER CHAPTER? Step into the future you've always dreamed of with the power of transformative rituals with the Mindful Subscription Box. Get a monthly box full of crystals, aromatherapy, and other spiritual tools worth $120. You deserve high-quality gems, crystals, oils, and mindfulness tools for self-care that truly work. It's a monthly dose of self-love delivered right to your door! Go to www.Mindfulsouls.com  and use Discount Code LORA25 for 25% off your order!

Send us Fan MailOne in six children has a developmental delay, and it takes an average of five years to get a diagnosis for a genetic disease. But it doesn't have to. The technology to get answers in 48 hours already exists.Katherine Stueland, CEO, GeneDx joins host John Driscoll to discuss why rare genetic diseases are far more common than most people realize, how whole genome sequencing is transforming pediatric care, and what it will take to bring precision medicine to every child who needs it.

At age 12, Dr. Chrystal Starbird stood by a pond after turning her mother in to the police. She watched tadpoles and fish move beneath the surface and found a strange kind of order. Science became her refuge long before it became her career. Years later, she built that refuge into a profession. She now serves as an Assistant Professor at the University of North Carolina, studies structural biology tied to cancer and Alzheimer's disease, and won Cell's first Rising Black Scientist Award in 2020. On paper, she fits the model of success. In practice, she had to fight for basic access at every stage.Conference travel required upfront cash she did not have. Networking favored pedigree over merit. Mentorship often depended on who knew your name in the room. Chrystal learned those rules, then chose to break them open for others.Oliver Bogler examines what Chrystal calls the advocacy tax. She has delivered over 70 invited talks. Nearly 40 percent focus on equity, mentorship, and policy. Academic reward systems do not count that labor toward tenure. She still does it.Through her leadership at the Life Science Editors Foundation, Chrystal helped build the JEDI program, which pairs underrepresented scientists with editors from journals like Cell and Nature. The program has supported over 100 awardees with more than 1,000 hours of mentorship. This episode exposes how biomedical science rewards output while ignoring the work required to make the system accessible. It also shows what happens when the people most affected refuse to step back.RELATED LINKSDr. Chrystal StarbirdStarbird LabLife Science Editors FoundationJEDI ProgramFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At 19, Jansher Naim went from sharp stomach pain to a Stage 4 fibrolamellar diagnosis that few doctors see and even fewer young adults survive. He pushed through 41 rounds of chemotherapy, a Whipple surgery, and months of isolation while his friends kept moving through normal college life. In the studio, Jansher sits beside his mother Sadia Siddiqui, who refused early defeat and helped overhaul his care team when the first plan offered little optimism. Now a Computer Science student at Columbia, Jansher lives in the uneasy space between remission and risk, managing fertility decisions, travel for ongoing care, and the strange pressure to look fine at 22. Together they describe what it takes to grow up fast inside a system that rarely knows what to do with young adults who refuse to disappear.RELATED LINKSJansher NaimSadia SiddiquiFibroFighters FoundationColumbia UniversityFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jessica Federer built her career inside the rooms where science, money, and power collide. As the first female Chief Digital Officer at Bayer, she helped steer a 120,000 person global company through the rise of digital medicine while confronting a harder truth: women were excluded from U.S. clinical trials until 1993. In this conversation, she explains how decades of “first in man” research shaped drug development, why women experience side effects at nearly 2x the rate of men, and how guidance on sex based differences did not arrive from the FDA until December 2025. She shares what it means to sit on a Yale Institutional Review Board, why clinical trial stipends over $3,000 get taxed, and why she believes participants deserve tax credits instead. From GLP 1 profits to $40,000,000 women's health funds that barely move the needle, this episode names the gaps and the opportunity hiding inside them. RELATED LINKSJessica Federer on LinkedInJessica Federer on InstagramYale School of Public HealthHealth of Women Investor SummitFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Monique Gore Massey spent 2.5 years cycling through New York City emergency rooms while her body shut down. Fevers hit 105. Her weight dropped from 122 pounds to 72 in 3 months. Hair fell out in clumps. No one ran an ANA test. Doctors blamed stress, old sports injuries, migraines. When a physician finally named it lupus, she added that she hoped it was not. Months later, Monique heard the words “get your affairs in order.”In this episode, Monique details living with lupus nephritis, pericarditis, fibromyalgia, and the daily math of survival. She recounts arriving at a patient conference shortly after coming off crutches and requesting elevator access for support, only to face resistance at a health summit that claimed to center patients. She breaks down what it costs when industry extracts lived experience for free and calls it engagement. Listeners will hear what invisible illness looks like in real time, how bias delays diagnosis, and why advocacy without strategy leaves patients exploited instead of respected.RELATED LINKSMonique Gore MasseyLupus Foundation of AmericaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode of Unsupervised Learning, Razib talks to Mike White, a Genetics professor at the Washington University in St. Louis. White has a position at the School of Medicine in St. Louis, where he leads a research team focused on understanding the biophysical architecture of regulatory DNA. He earned a B.A. in music before pivoting to the sciences, receiving his Ph.D. in Biochemistry from the University of Rochester in 2006 and completing a postdoctoral fellowship at Wash U under Dr. Barak Cohen. White's work combines functional genomics, synthetic biology, computational biology, and deep learning to decipher how cells interpret regulatory sequences. His lab aims to predict how non-coding genetic variations impact complex human traits and disease risk, while exploring how to apply transcriptional circuits for broader applications in health and agriculture. Razib first talks to White about the cultural, political and social winds moving through academia since 2010. How did academic science become so politically polarized, and what significance does it have for future funding streams? White brings his insights from the viewpoint of someone whose perch is in a medical school, and so somewhat at the margins of the cultural revolution sweeping through academia and even STEM. He notes it seems that the activist high tide peaked around 2020, though the hostility between the Right and institutional academia continues unabated, affecting NIH funding. Then White discusses where we are in terms of understanding gene regulation, and its importance in biological function. Razib and White review how almost 99% of the human genome does not code for proteins, so often it is called "junk DNA," but the reality is that there are other functions in that region, first and foremost, regulating and modifying protein expressing regions. Razib asks White where we are in human genomics more than 25 years after the draft, has it lived up to expectations? And where we are going in the future?

Teresa Baglietto has lived through the kind of compounded harm that exposes how thin the safety net really is. In this episode she walks through a life shaped by medical neglect, personal violence, and the exhausting labor of self advocacy. She nearly died after a C section when hospital staff failed to confirm she had urinated before discharge, spending 15 days hospitalized and separated from her newborn while facing the possibility of permanent damage. In 2013 she discovered an aggressive breast cancer and waited weeks for test results and surgery while administrators stalled and passed responsibility. Care only moved forward after she threatened public exposure. Teresa also speaks openly about surviving rape in high school, losing her father to cancer at age 48 when she was 10, and growing up without reliable adults in the room. She explains why it took 7 years to write her book, why she launched a podcast, and how sales grit becomes a survival tool when patients must fight systems designed to delay them. The conversation stays specific, unsentimental, and grounded in consequence.RELATED LINKSTeresa Baglietto on LinkedInThe Ripple Effect by Teresa BagliettoIn Shock PodcastIn Shock Podcast on InstagramCanvas Rebel interview with Teresa BagliettoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Episode 216 with Derrick Edem Akpalu, Co Founder and Chief Executive Officer of Revna Biosciences, a biotechnology company advancing precision medicine, genomics, and molecular diagnostics across Africa. Derrick is leading a mission to transform healthcare outcomes by building world class diagnostic and research capabilities that address some of the continent's most pressing medical challenges. Through Revna Biosciences, he is helping bring advanced genomic testing, clinical research partnerships, and personalised treatment selection closer to the patients and healthcare providers who need them most.Derrick explains why precision medicine could play a significant role in the future of healthcare across Africa, and why the continent's extraordinary genetic diversity presents a powerful opportunity to improve disease diagnosis, treatment, and drug development globally. From oncology and infectious disease genomics to biobanking and translational research, he shares how building local life sciences infrastructure can dramatically improve patient outcomes while enabling Africa to contribute more meaningfully to global biotechnology and medical research.Derrick also discusses the realities of building a deep science biotechnology company in Africa, the importance of international laboratory standards and global research partnerships, and why local diagnostic capacity is essential for strengthening healthcare sovereignty across the continent. More broadly, he explores how investment in health innovation, biotechnology, and medical research can unlock new economic opportunities, create high value scientific jobs, and position Africa as a global hub for life sciences discovery and healthcare innovation.What We Discuss With DerrickThe rise of precision medicine in Africa and why the continent's genetic diversity could reshape global healthcare innovation.Why building local molecular diagnostics and genomics infrastructure is essential for improving patient outcomes and strengthening healthcare sovereignty.How Revna Biosciences is developing biotechnology capability in Africa through genomics, biobanking, and clinical research partnerships.The realities of building a biotechnology and deep science startup in Africa and the challenges founders face beyond raising capital.Why investment in healthcare innovation, biotechnology, and life sciences should be viewed as critical economic infrastructure for Africa's future growth.Did you miss my previous episode where I discuss How Africa Can Build a Stronger Agribusiness Economy: Patient Capital, Food Security & Investment? Make sure to check it out!Connect with Terser:LinkedIn - Terser AdamuInstagram - unlockingafricaTwitter (X) - @TerserAdamuConnect with Derrick:LinkedIn -  Derrick Edem AkpaluMany of the businesses unlocking opportunities in Africa don't do it alone. If you'd like strategic support on entering or expanding across African markets, reach out to our partners ETK Group: www.etkgroup.co.ukinfo@etkgroup.co.uk

S3E2: Artificial Intelligence Continues to Reshape Healthcare -- But What if the Next Frontier Isn't in Imaging or Genomics, But in the Human Voice? Host: Frank Cutitta Guest: Henry O'Connell, CEO of Canary Speech To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Science likes to call itself a meritocracy. Angela Anderson and Brandi Mattson know better. Both served as editors at elite journals (Cell and Neuron), where a single decision could determine who gets tenure, funding, or obscurity. They watched brilliant data get filtered out because the authors did not know the unwritten rules controlled by 5 dominant publishing houses with profit margins higher than Google.In 2020, amid pandemic shutdowns and national reckoning over racial injustice, they co-founded a nonprofit to expose that hidden curriculum. Through the JEDI program, they provide 10 hours of free editorial consulting to scientists who lack access to elite networks. In 1 year alone, 25 awards helped researchers salvage canceled grants, secure NSF career funding, and rebuild careers derailed by rejection.This episode pulls back the curtain on the multibillion dollar publishing engine that profits from taxpayer funded science and reveals who gets heard, who gets sidelined, and how insiders are choosing to redistribute power.RELATED LINKSAngela AndersonBrandy MattsonLife Science EditorsLife Science Editors FoundationCellNeuronNational Science FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's episode of Out of Patients welcomes Dr Pamela Buchanan, an emergency room physician with over 20 years inside American medicine who refuses to sugarcoat what the job demands and what it destroys. She worked straight through COVID as protocols changed by the day and deaths arrived faster than anyone could process. She logged 80 to 100 hour weeks. She isolated from her family to avoid bringing the virus home. Over time, survival began to feel negotiable.Dr Buchanan speaks openly about burnout as emotional flatline and about physician suicide as a predictable outcome that leadership prefers to ignore. She describes the ER as the catch all for a broken system and explains why chronic care collapses there by design. She shares the reality of trying to access mental health care while still practicing medicine, calling dozens of therapists, getting nowhere, and spending $10,000 to $15,000 out of pocket just to stay alive and functional.Listeners will hear how neurodivergence shaped her career in emergency medicine, how race and trust intersect inside hospital walls, and why doctors are leaving in waves. This conversation carries clarity, anger, humor, and hard earned truth from someone who stayed long enough to name the damage.RELATED LINKSDr Pamela BuchananStrong MedicineDr Pamela Buchanan on LinkedInDr Pamela Buchanan on InstagramEmotional Flatline articleKevinMD essay by Dr Pamela BuchananFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Hair might seem trivial, but for many of us it carries history, identity, and meaning far beyond keratin. In this week's episode, both of our storytellers explore the unexpected power their hair holds.Part 1: Being half Navajo and half white, Carissa Sherman turns to genetics to better understand her identity. As she questions where she belongs, her hair becomes a quiet but powerful marker of how she sees herself.Part 2: Growing up, Ria Spencer believed “good hair” meant long hair but when a medical condition forces her to shave it all off, she's challenged to rethink what that belief really means.Carissa Sherman is Diné (Navajo) and from Arizona. She's a rising 5th year PhD Candidate in the Human Medical Genetics and Genomics program at the University of Colorado Anschutz Medical Campus. Carissa is a member of Dr. Katrina Claw's Lab. Her current work has involved community-based participatory research gathering perspectives of genetics research as well as examining population-level pharmacogenetic variation. Her research interests include examining ethical, legal, social and cultural implications of genetic research and learning potential ways to advance inclusivity and equity in public health medicine. She is interested in science policy and/or academia. Carissa and her husband like to craft, draw, go to renaissance fairs, and have two cats; she loves horror movies! Ria Spencer is an aspiring world traveler and wannabe foodie who's spent years belting classic rock and sweet soul music for marginally sober audiences with her band Girls on Top. She's also delighted to be a grown-ass woman who's lived long enough to have some stories to tell. Ria produced and hosted Where Are They Now: The GenX Years in the New York Frigid Festival and has also appeared in the No Name Comedy/Variety Show, RISK!, Better Said Than Done, Dead Rock Stars and The Volume Knob.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Barbara Paldus is the Founder and CEO of CODEX Labs, the sponsor of this episode.She grew up around Nobel Prize winners, built biotech manufacturing equipment for vaccines and cancer therapeutics, and then sold her company after an 8 year old threatened suicide.Her son's severe eczema pushed her into an unregulated $100,000,000,000 skincare market where parents are told to trust labels that nobody verifies. She explains how corticosteroid ladders leave patients with years long withdrawal, why U.S. ingredient oversight lags Europe, and how chemotherapy destroys the same skin and gut barriers seen in inflammatory disease.The conversation tracks the real stakes behind “clean” marketing: a child's immune system, hospital infections like MRSA, and patients trying to survive treatment without new damage. She also details the research path from Irish medical manuscripts to microbiome science and why sick populations become the only reliable regulators when policy fails.RELATED LINKSBarbara PaldusCodex LabsSekhmet VenturesDr Peter LioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Most doctors treat the average patient. But you are not average, and this episode gives you the precision medicine blueprint to treat yourself like the individual you are, using multi-omic testing, biohacking technology, and longevity science to optimize every layer of your biology. -Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey sits down with Dr. Anil Bajnath, a Board-Certified Family Physician, author of The Longevity Equation, and President and Founder of the American Board of Precision Medicine. He serves as Adjunct Professor at the George Washington University School of Medicine and CEO of the Institute for Human Optimization. Dr. Bajnath is certified through the Institute for Functional Medicine, board certified in anti-aging and regenerative medicine, and is one of the few clinicians actively applying genomics, transcriptomics, proteomics, and epigenetics together in a real clinical practice. Together, Dave and Dr. Bajnath break down why population-based medicine fails individuals, how functional medicine and precision science combine to unlock real human performance, and why your mitochondria sit at the foundation of every longevity strategy worth pursuing. They dig into how AI can help you decode your own inflammasome biology, why biohackers are using “sex drugs” to extend longevity, why vagal nerve stimulation directly suppresses the NLRP3 inflammasome, and which biomarkers like MMP9 and homocysteine mainstream medicine keeps ignoring. They also cover peptides, supplements, the dark side of metformin, microdosing for anti-aging, and why biohacking works best when it's personalized and precise. This is essential listening for anyone serious about longevity, smarter not harder health strategies, metabolism, sleep optimization, brain optimization, functional medicine, and taking full control of their biology. You'll Learn: Why precision medicine outperforms population-based health strategies for human performance How to layer genomics, transcriptomics, and proteomics into one complete biological picture Which longevity biomarkers your doctor is likely ignoring, including MMP9 and homocysteine How vagal nerve stimulation suppresses the NLRP3 inflammasome and drives anti-aging benefits The real story on metformin, peptides, and which supplements actually move the needle How AI can help you understand your own biology and act on it faster Why biohacking precision beats random stacking every time Thank you to our sponsors! • Igniton | Head over to Igniton.com and use code DAVE for an exclusive 15% off your first order. • BEYOND Biohacking Conference 2026 | Register with code DAVE300 for $300 off https://beyondconference.com • Caldera + Lab | Go to https://calderalab.com/DAVE and use code DAVE at checkout for 20% off your first order. • Screenfit | Get your at-home eye training program for 40% off using code DAVE at https://www.screenfit.com/dave. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: precision medicine, biohacking, Dave Asprey Cialis, Anil Bajnath, American Board of Precision Medicine, multi-omics, genomics, transcriptomics, proteomics, epigenetics, NLRP3 inflammasome, vagal nerve stimulation, MMP9, homocysteine, mitochondria, longevity, anti-aging, peptides, BPC-157, metformin, rapamycin, functional medicine, human performance, supplements, EGCG, exposome, nitric oxide, vascular health, metabolism, brain optimization, AI health, biohacking technology, Dave Asprey Sex Drugs Resources: • Learn More About Anil's Work And the Institute For Human Optimization At: https://ifho.org/ • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Trailer 00:53 – Intro to Precision Medicine 01:58 – Dr. Bajnath's Holistic Health Journey 05:03 – Pharmaceuticals vs. Supplements 07:58 – Peptides and Longevity Molecules 10:34 – Sexual Health and Vitality 13:56 – Vascular Health and Blood Flow 15:14 – Multi-Omics Approach 19:03 – DNA and Genomics 22:17 – Transcriptomics and RNA 24:24 – Proteomics and Inflammation Markers 32:00 – The Human Exposome 34:55 – Key Health Biomarkers 36:58 – Cell Membrane Dynamics 40:28 – Biological Investment Strategy 41:53 – Life Extension Possibilities 48:52 – Bioenergetics and Mitochondria 49:47 – Quantum Medicine and the Future 51:33 – Vagal Nerve Stimulation See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr Eugene Manley grew up in Detroit in the 1980s cycling through emergency rooms 20 to 30 times a year with asthma and anaphylaxis while hospital staff talked past his family and buried them in paperwork they could not decode. He responded by earning a BS in mechanical engineering an MS in biomedical engineering and a PhD in molecular biology cell biology and biochemistry. Along the way he tore his ACL training for a jiu jitsu black belt worked 86 straight days in a lab during his doctorate and learned how academic and clinical systems punish people who refuse to shrink.In this episode Manley walks through a recent post surgery ordeal at Mount Sinai Queens where staff falsified records attempted an illegal discharge and nearly sent him home on the wrong blood thinner. He explains how medical racism shows up in charts staffing and decision making and why measurable equity fails without accountability. Listeners hear how his STEMM and Cancer Health Equity Foundation builds pipelines for underrepresented students challenges clinical trial design and teaches patients how to protect themselves when institutions lie. RELATED LINKS• Eugene Manley Jr• STEMM and Cancer Health Equity Foundation• Village Voice• LUNGevity FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Talk Nerdy, Cara is joined by Bioethicist and Assistant Professor of Pediatrics at Stanford University, Dr. Daphne O. Martschenko. They discuss her book, What We Inherit: How New Technologies and Old Myths Are Shaping Our Genomic Future. Follow Daphne: @daphmarts  

Genomics researcher Dr. Robert Green explains how sequencing babies' DNA can reveal hidden health risks. This hour we explore where the benefits end and the ethical dilemmas begin.Guests include Dr. Robert Green, bioethicist and pediatrician Dr. Lainie Friedman Ross and genetic counselor Bethany Zettler.TED Radio Hour+ subscribers now get access to bonus episodes, with more ideas from TED speakers and a behind the scenes look with our producers. A Plus subscription also lets you listen to regular episodes (like this one!) without sponsors. Sign-up at plus.npr.org/ted.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy